Patents by Inventor Tanja Meister

Tanja Meister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND
    Publication number: 20240116900
    Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 11, 2024
    Inventors: Simona COTESTA, Heng GE, Marc GERSPACHER, Catherine LEBLANC, Bo LIU, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Tanja MEISTER, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Lijun XUE, Marie-Anne LOZAC'H, Ross STRANG
  • Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
    Patent number: 8987285
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 24, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister
  • PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF MULA (I), AND METHODS OF USE THEREOF
    Publication number: 20130252979
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral for mulation of this novel crystalline form, its preparation and use thereof.
    Type: Application
    Filed: December 5, 2011
    Publication date: September 26, 2013
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister